Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Probosciseson Apr 06, 2023 3:02pm
707 Views
Post# 35383632

Increase of Options from 10% to 14% of outstanding Shares

Increase of Options from 10% to 14% of outstanding SharesThis is discussed in the Management Information Circular.  It would increase options issued to insiders by about 2.9 miilion.  They say it is needed to match peer industries and retain and incentivize key personnel. This resolution will be voted on.  They describe the voting process and it sounds legit. 

Is this a further sign that ONC expects a deal to happen?
Is an increase in options needed to properly incentivize say James Parsons and Johnathan Rigby?
Will increased options give further incentive for ONC to consumate a deal now?
Is this just another means by which the already well-healed insiders accumulate more for themselves at the expense of investors?
How persuasive is management's rationalization for increased options?

Let the free speech begin.

<< Previous
Bullboard Posts
Next >>